Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D
For the third straight year, Lumenis wins an award recognizing outstanding medical companies and technologies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
